A paradoxical chemoresistance and tumor suppressive role of antioxidant in solid cancer cells: A strange case of Dr. Jekyll and Mr. Hyde

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Kwee, Jolie Kiemlian ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIOXIDANT; CATALASE; CERULOPLASMIN; CYSTEINE; FERRITIN; FREE RADICAL; GLUTATHIONE; METALLOTHIONEIN; PEROXIREDOXIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THIOREDOXIN;

APOPTOSIS ASSAY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; DRUG EFFICACY; HUMAN; HYPOXIA; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; REVIEW; SOLID TUMOR; SUPPLEMENTATION; TREATMENT OUTCOME; TUMOR CELL; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANTIOXIDANTS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TREATMENT OUTCOME;

EID: 84899567037     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/209845     Document Type: Review

References (105)

1. Fruehauf J. P., Meyskens F. L. Jr., Reactive oxygen species: a breath of life or death? Clinical Cancer Research 2007 13 3 789 794 2-s2.0-33847349283 10.1158/1078-0432.CCR-06-2082 (Pubitemid 46340350)
2. Circu M. L., Aw T. Y., Reactive oxygen species, cellular redox systems, and apoptosis. Free Radical Biology and Medicine 2010 48 6 749 762 2-s2.0-76049083966 10.1016/j.freeradbiomed.2009.12.022
3. Finkel T., Signal transduction by reactive oxygen species. Journal of Cell Biology 2011 194 1 7 15 2-s2.0-79960286223 10.1083/jcb.201102095
4. Dodson M., Darley-Usmar V., Zhang J., Cellular metabolic and autophagic pathways: traffic control by redox signaling. Free Radical Biology and Medicine 2013 63 207 221 10.1016/j.freeradbiomed.2013.05.014
5. Jimenez-Del-Rio M., Velez-Pardo C., The bad, the good, and the ugly about oxidative stress. Oxidative Medicine and Cellular Longevity 2012 2012 13 163913 10.1155/2012/163913
6. Kobliakov V. A., Mechanisms of tumor promotion by reactive oxygen species. Biochemistry (Moscow) 2010 75 6 675 685 2-s2.0-77955537622 10.1134/S0006297910060015
7. Beckman J. S., Koppenol W. H., Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. American Journal of Physiology: Cell Physiology 1996 271 5 C1424 C1437 2-s2.0-0029805172
8. Stamler J. S., Singel D. J., Loscalzo J., Biochemistry of nitric oxide and its redox-activated forms. Science 1992 258 5090 1898 1902 2-s2.0-0027104253 (Pubitemid 23026727)
9. Loscalzo J., The identification of nitric oxide as endothelium-derived relaxing factor. Circulation Research 2013 113 2 100 103 10.1161/CIRCRESAHA.113. 301577
10. Fridovich I., Oxygen toxicity: a radical explanation. The Journal of Experimental Biology 1998 201 8 1203 1209 2-s2.0-0032053161 (Pubitemid 28278324)
11. Kalyanaraman B., Teaching the basics of redox biology to medical and graduate students: oxidants, antioxidants and disease mechanisms. Redox Biology 2013 1 1 244 257 10.1016/j.redox.2013.01.014
12. Olsen L. F., Issinger O. G., Guerra B., The yin and yang of redox regulation. Redox Report 2013 18 6 245 252
13. Ježek P., Hlavatá L., Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organism. The International Journal of Biochemistry and Cell Biology 2005 37 12 2478 2503 2-s2.0-25844520458 10.1016/j.biocel.2005.05.013 (Pubitemid 41400319)
14. Poyton R. O., Ball K. A., Castello P. R., Mitochondrial generation of free radicals and hypoxic signaling. Trends in Endocrinology and Metabolism 2009 20 7 332 340 2-s2.0-69849097192 10.1016/j.tem.2009.04.001
15. Quinlan C. L., Perevoshchikova I. V., Hey-Mogensen M., Sites of reactive oxygen species generation by mitochondria oxidizing different substrates. Redox Biology 2013 1 1 304 312
16. Lambeth J. D., Kawahara T., Diebold B., Regulation of Nox and Duox enzymatic activity and expression. Free Radical Biology and Medicine 2007 43 3 319 331 2-s2.0-34250888056 10.1016/j.freeradbiomed.2007.03.028 (Pubitemid 46978416)
17. Brandes R. P., Weissmann N., Schröder K., Nox family NADPH oxidases in mechano-transduction: mechanisms and consequences. Antioxidants and Redox Signaling 2014 20 6 887 898 10.1089/ars.2013.5414
18. Cantu-Medellin N., Kelley E. E., Xanthine oxidoreductase-catalyzed reactive species generation: a process in critical need of reevaluation. Redox Biology 2013 1 1 353 358
19. Lugrin J., Rosenblatt-Velin N., Parapanov R., The role of oxidative stress during inflammatory processes. Biological Chemistry 2014 395 2 203 230
20. Fuchs-Tarlovsky V., Role of antioxidants in cancer therapy. Nutrition 2012 29 1 15 29
21. Block K. I., Koch A. C., Mead M. N., Tothy P. K., Newman R. A., Gyllenhaal C., Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. International Journal of Cancer 2008 123 6 1227 1239 2-s2.0-49749097982 10.1002/ijc.23754
22. Denekamp J., Daşu A., Waites A., Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy? Advances in Enzyme Regulation 1998 38 1 281 299 2-s2.0-0345055815 10.1016/S0065-2571(97)00015-0 (Pubitemid 28381396)
23. Cooper C., Liu G.-Y., Niu Y.-L., Santos S., Murphy L. C., Watson P. H., Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor α in human breast carcinoma. Clinical Cancer Research 2004 10 24 8720 8727 2-s2.0-11144231029 10.1158/1078-0432.CCR-04-1235 (Pubitemid 40053441)
24. Hsieh C.-H., Lee C.-H., Liang J.-A., Yu C.-Y., Shyu W.-C., Cycling hypoxia increases U87 glioma cell radioresistance via ROS induced higher and long-term HIF-1 signal transduction activity. Oncology Reports 2010 24 6 1629 1636 2-s2.0-78649396776 10.3892/or-00001027
25. Liu Y., Song X., Wang X., Wei L., Xiuju X., Shuanghu Yuan S. Y., Liyan Lv L. L., Effect of chronic intermittent hypoxia on biological behavior and hypoxia-associated gene expression in lung cancer cells. Journal of Cellular Biochemistry 2010 111 3 554 563 2-s2.0-78651311704 10.1002/jcb.22739
26. Bhaskara V. K., Mohanam I., Rao J. S., Mohanam S., Intermittent hypoxia regulates stem-like characteristics and differentiation of neuroblastoma cells. PLoS ONE 2012 7 2 2-s2.0-84857186454 10.1371/journal.pone.0030905 e30905
27. Whelan K. A., Reginato M. J., Surviving without oxygen: hypoxia regulation of mammary morphogenesis and anoikis. Cell Cycle 2011 10 14 2287 2294 2-s2.0-79960456668 10.4161/cc.10.14.16532
28. Rademakers S. E., Span P. N., Kaanders J. H. A. M., Sweep F. C. G. J., van der Kogel A. J., Bussink J., Molecular aspects of tumour hypoxia. Molecular Oncology 2008 2 1 41 53 2-s2.0-43649107785 10.1016/j.molonc.2008.03.006
29. Strese S., Fryknäs M., Larsson R., Effects of hypoxia on human cancer cell line chemosensitivity. BMC Cancer 2013 13 331 1 11 10.1186/1471-2407-13-1
30. Yang Y., Karakhanova S., Werner J., Reactive oxygen species in cancer biology and anticancer therapy. Current Medicinal Chemistry 2013 20 30 3677 3692 10.2174/0929867311320999165
31. Hsieh C. H., Wu C. P., Lee H. T., NADPH oxidase subunit 4 mediates cycling hypoxia-promoted radiation resistance in glioblastoma multiforme. Free Radical Biology and Medicine 2012 53 4 649 658 10.1016/j.freeradbiomed.2012.06. 009
32. Flamant L., Roegiers E., Pierre M., TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. BMC Cancer 2012 12 391 1 16 10.1186/1471-2407-12-1
33. Rhim T., Lee D. Y., Lee M., Hypoxia as target for tissue specific gene therapy. Journal of Controlled Release 2013 172 2 484 494
34. Miyata T., Takizawa S., van Ypersele de Strihou C., Hypoxia. 1. Intracellular sensors for oxygen and oxidative stress: novel therapeutic targets. American Journal of Physiology: Cell Physiology 2011 300 2 C226 C231 2-s2.0-79251535600 10.1152/ajpcell.00430.2010
35. Kim J.-W., Gao P., Dang C. V., Effects of hypoxia on tumor metabolism. Cancer and Metastasis Reviews 2007 26 2 291 298 2-s2.0-34547130302 10.1007/s10555-007-9060-4 (Pubitemid 47103157)
36. Nanduri J., Wang N., Yuan G., Khan S. A., Souvannakitti D., Peng Y.-J., Kumar G. K., Garcia J. A., Prabhakar N. R., Intermittent hypoxia degrades HIF-2 α via calpains resulting in oxidative stress: implications for recurrent apnea-induced morbidities. Proceedings of the National Academy of Sciences of the United States of America 2009 106 4 1199 1204 2-s2.0-59049086571 10.1073/pnas.0811018106
37. Keith B., Johnson R. S., Simon M. C., HIF1 α and HIF2 α: sibling rivalry in hypoxic tumour growth and progression. Nature Reviews Cancer 2012 12 1 9 22 2-s2.0-84655161946 10.1038/nrc3183
38. Nanduri J., Vaddi D. R., Khan S. A., Xanthine oxidase mediates hypoxia-inducible factor-2 α degradation by intermittent hypoxia. PLoS ONE 2013 8 10 e75838
39. Rundqvist H., Johnson R. S., Tumour oxygenation: implications for breast cancer prognosis. Journal of Internal Medicine 2013 274 2 105 112 10.1111/joim.12091
40. Ramanathan B., Jan K.-Y., Chen C.-H., Hour T.-C., Yu H.-J., Pu Y.-S., Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Research 2005 65 18 8455 8460 2-s2.0-24944486664 10.1158/0008-5472.CAN- 05-1162 (Pubitemid 41330613)
41. Woolston C. M., Zhang L., Storr S. J., Al-Attar A., Shehata M., Ellis I. O., Chan S. Y., Martin S. G., The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer. Modern Pathology 2012 25 8 1106 1116 2-s2.0-84859293993 10.1038/modpathol.2012.60
42. Brozovic A., Ambriović-Ristov A., Osmak M., The relationship between cisplatin-Induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Critical Reviews in Toxicology 2010 40 4 347 359 2-s2.0-77949808915 10.3109/10408441003601836
43. Vincent D. T., Ibrahim Y. F., Espey M. G., The role of antioxidant in the era of cardio-oncology. Cancer Chemotherapy and Pharmacology 2013 72 6 1157 1168 10.1007/s00280-013-2260-4
44. Glorieux C., Dejeans N., Sid B., Beck R., Calderon P. B., Verrax J., Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy. Biochemical Pharmacology 2011 82 10 1384 1390 2-s2.0-80054693822 10.1016/j.bcp.2011.06.007
45. Hanschmann E. M., Godoy J. R., Berndt C., Thioredoxins, glutaredoxins, and peroxiredoxins-molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling. Antioxidants and Redox Signaling 2013 19 13 1539 1605 10.1089/ars.2012.4599
46. Rio D. D., Mateos A. R., Spencer J. P. E., Dietary (poly) phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxidants and Redox Signaling 2013 18 14 1818 1892
47. Zalewska M., Trefon J., Milnorowicz H., The role of metallothionein interactions with other proteins. Proteomics 2014 10.1002/pmic 201300496
48. Romero-Canelón I., Sadler P. J., Next-generation metal anticancer complexes: multitargeting via redox modulation. Inorganic Chemistry 2013 52 21 12276 12291 10.1021/ic400835n
49. Goodman M., Bostick R. M., Kucuk O., Jones D. P., Clinical trials of antioxidants as cancer prevention agents: past, present, and future. Free Radical Biology and Medicine 2011 51 5 1068 1084 2-s2.0-80051671704 10.1016/j.freeradbiomed.2011.05.018
50. Bjelakovic G., Nikolova D., Gluud C., Antioxidant supplements and mortality. Current Opinion in Clinical Nutrition and Metabolic Care 2014 17 1 40 44
51. 2 generation: redox signaling and oxidative stress. The Journal Biological Chemistry 2014 10.1074/jbc.R113.544635
52. Poynton R. A., Hampton M. B., Peroxiredoxins as biomarkers of oxidative stress. Biochimica et Biophysica Acta 2014 1840 2 906 912 10.1016/j.bbagen.2013. 08.001
53. Merino J. J., Roncero C., Oset-Gasque M. J., Antioxidant and protective mechanisms against hypoxia and hypoglycaemia in cortical neurons in vitro. International Journal of Molecular Sciences 2014 15 2 2475 2493 10.3390/ijms15022475
54. Khramtsov V. V., Gillies R. J., Janus-faced tumor microenvironment and redox. Antioxidant and Redox Signaling 2014
55. Lushchak V. I., Glutathione homeostasis and fuctions: potential targets for medical interventions. Journal of Amino Acids 2012 2012 26 736837 10.1155/2012/736837
56. Wu J. H., Batist G., Glutathione and glutathione analogues, therapeutic potentials. Biochimica et Biophysica Acta 2013 1830 5 3350 3353
57. Townsend D. M., Tew K. D., Tapiero H., The importance of glutathione in human disease. Biomedicine and Pharmacotherapy 2003 57 3 145 155 2-s2.0-0037733975 10.1016/S0753-3322(03)00043-X (Pubitemid 36740460)
58. Traverso N., Ricciarelli R., Nitti M., Role of glutathione in cancer progression and chemoresistance. Oxidative Medicine and Cellular Longevity 2013 2013 10 972913 10.1155/2013/972913
59. Kwee J. K., Luque D. G., Ferreira A. C. D. S., Vasconcelos F. D. C., Silva K. L., Klumb C. E., Maia R. C., Modulation of reactive oxygen species by antioxidants in chronic myeloid leukemia cells enhances imatinib sensitivity through survivin downregulation. Anti-Cancer Drugs 2008 19 10 975 981 2-s2.0-54249133182 10.1097/CAD.0b013e3283140c6f
60. Yang P., Ebbert J. O., Sun Z., Weinshilboum R. M., Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. Journal of Clinical Oncology 2006 24 11 1761 1769 2-s2.0-33645804599 10.1200/JCO.2005.02.7110 (Pubitemid 46622148)
61. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation. Cell 2011 144 5 646 674 2-s2.0-79952284127 10.1016/j.cell.2011.02.013
62. Fiaschi T., Chiarugi P., Oxidative stress, tumor microenvironment, and metabolic reprogramming: a diabolic liaison. International Journal of Cell Biology 2012 2012 8 762825 10.1155/2012/762825
63. Hu X., Xuan Y., Bypassing cancer drug resistance by activating multiple death pathways-a proposal from the study of circumventing cancer drug resistance by induction of necroptosis. Cancer Letters 2008 259 2 127 137 2-s2.0-37049003301 10.1016/j.canlet.2007.11.007 (Pubitemid 50015326)
64. Köberle B., Tomicic M. T., Usanova S., Kaina B., Cisplatin resistance: preclinical findings and clinical implications. Biochimica et Biophysica Acta 2010 1806 2 172 182 2-s2.0-77957375221 10.1016/j.bbcan.2010.07. 004
65. 3-induced ovarian cancer cell death: Oxidative stress-independent and -dependent cytotoxic potentiation. International Journal of Oncology 2011 38 6 1731 1739 2-s2.0-79955833044 10.3892/ijo.2011.986
66. Jozefczak M., Remans T., Vangronsveld J., Cuypers A., Glutathione is a key player in metal-induced oxidative stress defenses. International Journal of Molecular Sciences 2012 13 3 3145 3175 2-s2.0-84858974142 10.3390/ijms13033145
67. Bailey H. H., Mulcahy R. T., Tutsch K. D., Arzoomanian R. Z., Alberti D., Tombes M. B., Wilding G., Pomplun M., Spriggs D. R., Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. Journal of Clinical Oncology 1994 12 1 194 205 2-s2.0-0028157817 (Pubitemid 24020640)
68. O'Dwyer P. J., Hamilton T. C., LaCreta F. P., Gallo J. M., Kilpatrick D., Halbherr T., Brennan J., Bookman M. A., Hoffman J., Young R. C., Comis R. L., Ozols R. F., Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. Journal of Clinical Oncology 1996 14 1 249 256 2-s2.0-9044254931 (Pubitemid 26020021)
69. Bailey H. H., Ripple G., Tutsch K. D., Arzoomanian R. Z., Alberti D., Feierabend C., Mahvi D., Schink J., Pomplun M., Mulcahy R. T., Wilding G., Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. Journal of the National Cancer Institute 1997 89 23 1789 1796 2-s2.0-0030658870 (Pubitemid 27516233)
70. Bailey H. H., L-S,R-buthionine sulfoximine: historical development and clinical issues. Chemico-Biological Interactions 1998 111-112 239 254 2-s2.0-4243987802 10.1016/S0009-2797(97)00164-6 (Pubitemid 28271948)
71. Hamilton D., Batist G., Glutathione analogues in cancer treatment. Current Oncology Reports 2004 6 2 116 122 2-s2.0-2342656304 (Pubitemid 38898839)
72. Salmena L., Carracedo A., Pandolfi P. P., Tenets of PTEN tumor suppression. Cell 2008 133 3 403 414 2-s2.0-43049128529 10.1016/j.cell.2008.04. 013 (Pubitemid 351622014)
73. Saha T., Rih J. K., Rosen E. M., BRCA1 down-regulates cellular levels of reactive oxygen species. The FEBS Letters 2009 583 9 1535 1543 2-s2.0-67349272025 10.1016/j.febslet.2009.04.005
74. Huang Z., Zuo L., Zhang Z., Liu J., Chen J., Dong L., Zhang J., 3,3′-Diindolylmethane decreases VCAM-1 expression and alleviates experimental colitis via a BRCA1-dependent antioxidant pathway. Free Radical Biology and Medicine 2011 50 2 228 236 2-s2.0-78651238595 10.1016/j. freeradbiomed.2010.10.703
75. Vurusaner B., Poli G., Basaga H., Tumor suppressor genes and ROS: complex networks of interactions. Free Radical Biology and Medicine 2012 52 1 7 18 2-s2.0-84655169936 10.1016/j.freeradbiomed.2011.09.035
76. Luo H., Yang Y., Duan J., PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells. Cell Death and Disease 2013 4, article e481 10.1038/cddis.2013.3
77. Meng F. G., Zhang Z. Y., Redox regulation of protein tyrosine phosphatase activity by hydroxyl radical. Biochimica et Biophysica Acta 2013 1834 1 464 469
78. Kim S. J., Jung H. J., Lim C. J., Reactive oxygen species-dependent down-regulation of tumor suppressor genes PTEN, USP28, DRAM, TIGAR, and CYLD under oxidative stress. Biochemical Genetics 2013 51 11-12 901 915 10.1007/s10528-013-9616-7
79. Tutt A., Ashworth A., The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends in Molecular Medicine 2002 8 12 571 576 2-s2.0-0036893150 10.1016/S1471-4914(02)02434-6 (Pubitemid 35408215)
80. Turner N., Tutt A., Ashworth A., Hallmarks of 'BRCAness' in sporadic cancers. Nature Reviews Cancer 2004 4 10 814 819 2-s2.0-4944229642 10.1038/nrc1457 (Pubitemid 39331153)
81. Roy R., Chun J., Powell S. N., BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nature Reviews Cancer 2012 12 1 68 78 2-s2.0-84555196106 10.1038/nrc3181
82. Li M. L., Greenberg R. A., Links between genome integrity and BRCA1 tumor suppression. Trends in Biochemical Sciences 2012 37 10 418 424 10.1016/j.tibs.2012.06.007
83. Foulkes W. D., Shuen A. Y., In brief: BRCA1 and BRCA2. Journal of Pathology 2013 230 4 347 349 10.1002/path.4205
84. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W., Bell R., Rosenthal J., Hussey C., Tran T., McClure M., Frye C., Hattier T., Phelps R., Haugen-Strano A., A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994 266 5182 66 71 2-s2.0-0028113345 (Pubitemid 24345325)
85. Futreal P. A., Liu Q., Shattuck-Eidens D., Cochran C., Harshman K., Tavtigian S., Bennett L. M., Haugen-Strano A., Swensen J., Miki Y., Eddington K., McClure M., Frye C., Weaver-Feldhaus J., Ding W., Gholami Z., Soderkvist P., Terry L., Jhanwar S., BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994 266 5182 120 122 2-s2.0-0028073794 (Pubitemid 24345332)
86. Birkbak N. J., Kochupurakkai B., Izarzugaza J. M. G., Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLos ONE 2013 08 11 e80023
87. Fan S., Wang J.-A., Yuan R.-Q., Ma Y. X., Meng Q., Erdos M. R., Brody L. C., Goldberg I. D., Rosen E. M., BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene 1998 16 23 3069 3082 2-s2.0-0032507879 (Pubitemid 28297729)
88. Castro E., Goh C., Olmos D., Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. Journal of Clinical Oncology 2013 31 14 1748 1757 10.1200/JCO.2012.43.1882
89. de Luca P., Moiola C. P., Zalazar F., BRCA1 and p53 regulate critical prostate cancer pathways. Prostate Cancer and Prostatic Diseases 2013 16 3 233 238 10.1038/pcan.2013.12
90. Passaro A., Palazzo A., Trenta P., Molecular and clinical analysis of predictive biomarkers in non-small-cell lung cancer. Current Medicinal Chemistry 2012 19 22 3689 3700 10.2174/092986712801661149
91. Pesta M., Kulda V., Fiala O., Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer. Anticancer Research 2012 32 11 5003 5010
92. Harada H., Miyamoto K., Yamashita Y., Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non-small cell lung cancer. Cancer 2013 119 4 792 798
93. Tiseo M., Bordi P., Bortesi B., ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. British Journal of Cancer 2013 108 8 1695 1703 10.1038/bjc.2013.127
94. Sung M., Giannakakou P., BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling. Oncogene 2014 33 11 1418 1428 10.1038/onc.2013.85
95. Axilbund J. E., Wiley E. A., Genetic testing by cancer site: pancreas. Cancer Journal 2012 18 4 350 354
96. Wang T., Wentz S. C., Ausborn N. L., Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic ductal adenocarcinoma. Pancreas 2013 42 6 977 982
97. Fauman E. B., Saper M. A., Structure and function of the protein tyrosine phosphatases. Trends in Biochemical Sciences 1996 21 11 413 417 2-s2.0-0030296632 10.1016/S0968-0004(96)10059-1 (Pubitemid 26393727)
98. Tonks N. K., Protein tyrosine phosphatases: from genes, to function, to disease. Nature Reviews Molecular Cell Biology 2006 7 11 833 846 2-s2.0-33750299450 10.1038/nrm2039 (Pubitemid 44627477)
99. Hunter T., Tyrosine phosphorylation: thirty years and counting. Current Opinion in Cell Biology 2009 21 2 140 146 2-s2.0-63749113783 10.1016/j.ceb.2009.01.028
100. Tautz L., Critton D. A., Grotegut S., Protein tyrosine phosphatases: structure, function, and implication in human disease. Methods in Molecular Biology 2013 1053 179 221
101. Tonks N. K., Redox redux: revisiting PTPs and the control of cell signaling. Cell 2005 121 5 667 670 2-s2.0-20444400257 10.1016/j.cell.2005.05.016 (Pubitemid 40797589)
102. Pires M. M., Hopkins B. D., Saal L. H., Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells. Cancer Biology and Therapy 2013 14 3 246 253 10.4161/cbt.23297
103. Saal L. H., Gruvberger-Saal S. K., Persson C., Lövgren K., Jumppanen M., Staaf J., Jönsson G., Pires M. M., Maurer M., Holm K., Koujak S., Subramaniyam S., Vallon-Christersson J., Olsson H., Su T., Memeo L., Ludwig T., Ethier S. P., Krogh M., Szabolcs M., Murty V. V. V. S., Isola J., Hibshoosh H., Parsons R., Borg Å., Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nature Genetics 2008 40 1 102 107 2-s2.0-37549020704 10.1038/ng.2007.39
104. Bensaad K., Tsuruta A., Selak M. A., Vidal M. N. C., Nakano K., Bartrons R., Gottlieb E., Vousden K. H., TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006 126 1 107 120 2-s2.0-33745918951 10.1016/j.cell.2006. 05.036 (Pubitemid 44040989)
105. Bensaad K., Cheung E. C., Vousden K. H., Modulation of intracellular ROS levels by TIGAR controls autophagy. The EMBO Journal 2009 28 19 3015 3026 2-s2.0-70350575440 10.1038/emboj.2009.242